GNLX GENELUX Corp
Nasdaq · SEC CIK 1231457 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $330.8K 19 sales by 6 insiders
- Filings on record
- 167 since 2023-01-30, latest 2026-09-02 19:05
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Zindrick Thomas | Pres, CEO | — | $117.7K |
| Thomas John | Dir | — | $108.8K |
| Smither John W | Dir | — | $34.9K |
| Cappello Joseph | Chief Technical Off | — | $34.0K |
| Yu Yong | SVP, Clinical Development | — | $32.6K |
| Smalling Ralph | Head of Regulatory | — | $2,804 |
| Pulisic Matthew | CFO | — | — |
| Mirabelli Mary | Dir | — | — |
| Groen Eric | GC | — | — |
| Tyree James L | Dir | — | — |
Transactions 160
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-12-08 | 2023-12-07 | GNLX | Yu Yong | VP, Clinical Trial Ops | S - Sale | $11.85 | -36.8K | 32.5K | -53% | -$436.1K | |
| 2023-11-22 | 2023-11-21 | GNLX | Yu Yong | VP, Clinical Trial Ops | S - Sale | $10.26 | -18.7K | 69.3K | -21% | -$191.5K | |
| M | 2023-11-21 | 2023-11-17+ | GNLX | Yu Yong | VP, Clinical Trial Ops | S - Sale | $11.61 | -18.1K | 102.6K | -15% | -$210.5K |
| I | 2023-10-26 | 2023-10-25 | GNLX | Szalay Aladar | 10% | S - Sale | $19.40 | -5,704 | 1.37M | -0.4% | -$110.7K |
| I | 2023-10-25 | 2023-10-23 | GNLX | Szalay Aladar | 10% | S - Sale | $19.97 | -50.0K | 1.38M | -4% | -$998.2K |
| D | 2023-10-25 | 2023-10-24 | GNLX | Yu Yong | VP, Clinical Trial Ops | S - Sale+OE | $19.11 | -5,200 | 106.1K | -5% | -$99.4K |
| D | 2023-10-25 | 2023-10-24 | GNLX | Yu Yong | VP, Clinical Trial Ops | M - OptEx | $6.00 | +5,200 | 111.3K | +5% | +$31.2K |
| M | 2023-10-16 | 2023-10-16 | GNLX | Thomas John | Dir | S - Sale | $20.71 | -3,333 | 473.3K | -0.7% | -$69.0K |
| D | 2023-10-11 | 2023-10-10 | GNLX | Yu Yong | VP, Clinical Trial Ops | M - OptEx | $6.00 | +5,200 | 111.3K | +5% | +$31.2K |
| DM | 2023-10-11 | 2023-10-10 | GNLX | Yu Yong | VP, Clinical Trial Ops | S - Sale+OE | $22.01 | -5,200 | 106.5K | -5% | -$114.5K |
| MI | 2023-10-10 | 2023-10-05 | GNLX | Szalay Aladar | 10% | S - Sale | $24.93 | -14.3K | 1.43M | -1.0% | -$355.3K |
| I | 2023-10-04 | 2023-10-03 | GNLX | Szalay Aladar | 10% | S - Sale | $25.49 | -75.7K | 1.44M | -5% | -$1.93M |
| MI | 2023-09-29 | 2023-09-27+ | GNLX | Szalay Aladar | 10% | S - Sale | $24.41 | -13.5K | 1.52M | -0.9% | -$330.7K |
| MI | 2023-09-27 | 2023-09-25+ | GNLX | Szalay Aladar | 10% | S - Sale | $24.38 | -42.3K | 1.56M | -3% | -$1.03M |
| DM | 2023-09-27 | 2023-09-26 | GNLX | Yu Yong | VP, Clinical Trial Ops | S - Sale+OE | $23.56 | -5,200 | 109.5K | -5% | -$122.5K |
| D | 2023-09-27 | 2023-09-26 | GNLX | Yu Yong | VP, Clinical Trial Ops | M - OptEx | $6.00 | +5,200 | 111.3K | +5% | +$31.2K |
| MI | 2023-09-25 | 2023-09-21+ | GNLX | Szalay Aladar | 10% | S - Sale | $27.85 | -16.6K | 1.59M | -1% | -$462.0K |
| D | 2023-09-21 | 2023-09-20 | GNLX | Yu Yong | VP, Clinical Trial Ops | M - OptEx | $6.00 | +6,000 | 112.1K | +6% | +$36.0K |
| D | 2023-09-21 | 2023-09-20 | GNLX | Yu Yong | VP, Clinical Trial Ops | S - Sale+OE | $27.96 | -6,000 | 106.1K | -5% | -$167.8K |
| D | 2023-09-21 | 2023-09-20 | GNLX | Ryder Sean | GC | S - Sale+OE | $30.00 | -10.0K | 572 | -95% | -$300.0K |
| D | 2023-09-21 | 2023-09-20 | GNLX | Ryder Sean | GC | M - OptEx | $6.00 | +10.0K | 10.6K | +1,748% | +$60.0K |
| MI | 2023-09-20 | 2023-09-18 | GNLX | Szalay Aladar | 10% | S - Sale | $23.29 | -30.3K | 7,927 | -79% | -$705.6K |
| M | 2023-09-20 | 2023-09-19 | GNLX | Szalay Aladar | 10% | S - Sale | $26.45 | -32.2K | 8,247 | -80% | -$850.9K |
| M | 2023-09-18 | 2023-09-15+ | GNLX | Thomas John | Dir | S - Sale | $23.45 | -6,667 | 479.1K | -1% | -$156.3K |
| D | 2023-09-18 | 2023-09-15 | GNLX | Yu Yong | VP, Clinical Trial Ops | M - OptEx | $6.00 | +10.4K | 116.5K | +10% | +$62.4K |
| DM | 2023-09-18 | 2023-09-15 | GNLX | Yu Yong | VP, Clinical Trial Ops | S - Sale+OE | $21.89 | -10.4K | 110.8K | -9% | -$227.6K |
| MI | 2023-09-15 | 2023-09-13+ | GNLX | Szalay Aladar | 10% | S - Sale | $21.80 | -44.3K | 35.3K | -56% | -$965.8K |
| 2023-09-15 | 2023-09-13 | GNLX | Yu Yong | VP, Clinical Trial Ops | S - Sale | $21.14 | -29.8K | 106.1K | -22% | -$630.0K | |
| 2023-09-14 | 2023-09-13 | GNLX | Smither John W | Dir | S - Sale | $20.78 | -900 | 6,920 | -12% | -$18.7K | |
| D | 2023-09-13 | 2023-09-11 | GNLX | Smither John W | Dir | A - Grant | $0.00 | +6,920 | 7,820 | +769% | $0 |
| D | 2023-09-13 | 2023-09-11 | GNLX | Tyree James L | Dir | A - Grant | $0.00 | +3,460 | 12.5K | +38% | $0 |
| D | 2023-09-13 | 2023-09-11 | GNLX | Mirabelli Mary | Dir | A - Grant | $0.00 | +3,460 | 4,460 | +346% | $0 |
| D | 2023-09-13 | 2023-09-11 | GNLX | Thomas John | Dir | A - Grant | $0.00 | +3,460 | 482.5K | +0.7% | $0 |
| MI | 2023-09-13 | 2023-09-11+ | GNLX | Szalay Aladar | 10% | S - Sale | $22.23 | -52.6K | 122.9K | -30% | -$1.17M |
| D | 2023-09-12 | 2023-09-11 | GNLX | Smalling Ralph | Head of Regulatory | A - Grant | $0.00 | +10.0K | 12.1K | +484% | $0 |
| D | 2023-09-12 | 2023-09-11 | GNLX | Jewett Caroline | Head of Quality | A - Grant | $0.00 | +20.0K | 21.1K | +1,762% | $0 |
| MI | 2023-09-11 | 2023-09-07+ | GNLX | Szalay Aladar | 10% | S - Sale | $23.57 | -37.3K | 134.9K | -22% | -$878.7K |
| 2023-08-30 | 2023-08-30 | GNLX | Yu Yong | VP, Clinical Trial Ops | S - Sale | $24.70 | -19.8K | 135.9K | -13% | -$489.1K | |
| 2023-08-22 | 2023-08-18 | GNLX | Zindrick Thomas | Pres, CEO, Dir | S - Sale | $23.73 | -8,349 | 14.7K | -36% | -$198.1K | |
| 2023-08-22 | 2023-08-18 | GNLX | Ryder Sean | GC | S - Sale | $23.73 | -328 | 572 | -36% | -$7,783 | |
| 2023-08-22 | 2023-08-18 | GNLX | Yu Yong | VP, Clinical Trial Ops | S - Sale | $23.73 | -3,265 | 155.7K | -2% | -$77.5K | |
| 2023-08-22 | 2023-08-18 | GNLX | Jewett Caroline | Head of Quality | S - Sale | $23.73 | -515 | 1,135 | -31% | -$12.2K | |
| 2023-08-22 | 2023-08-18 | GNLX | Cappello Joseph | VP, Pharmaceutical Development | S - Sale | $23.73 | -3,265 | 5,735 | -36% | -$77.5K | |
| 2023-08-22 | 2023-08-18 | GNLX | Samuelson Doug | CFO | S - Sale | $23.73 | -1,297 | 2,303 | -36% | -$30.8K | |
| 2023-08-22 | 2023-08-18 | GNLX | Smalling Ralph | Head of Regulatory | S - Sale | $23.73 | -935 | 2,065 | -31% | -$22.2K | |
| 2023-05-02 | 2023-02-17 | GNLX | Tyree James L | Dir | A - Grant | $0.00 | +9,000 | 9,000 | New | $0 | |
| 2023-05-02 | 2023-02-17 | GNLX | Cappello Joseph | VP, Pharmaceutical Development | A - Grant | $0.00 | +9,000 | 9,000 | New | $0 | |
| 2023-05-02 | 2023-02-17 | GNLX | Zhang Qian | Associate VP, Research | A - Grant | $0.00 | +6,000 | 139.3K | +5% | $0 | |
| 2023-05-02 | 2023-02-17 | GNLX | Ryder Sean | GC | A - Grant | $0.00 | +900 | 900 | New | $0 | |
| 2023-05-02 | 2023-02-17 | GNLX | Samuelson Doug | CFO | A - Grant | $0.00 | +3,600 | 3,600 | New | $0 | |
| 2023-05-02 | 2023-02-17 | GNLX | Yu Tony | VP, Clinical Trial Ops | A - Grant | $0.00 | +9,000 | 159.0K | +6% | $0 | |
| 2023-05-02 | 2023-02-17 | GNLX | Woodward Gabe | Dir | A - Grant | $0.00 | +1,000 | 4,186 | +31% | $0 | |
| 2023-05-02 | 2023-02-27 | GNLX | Zindrick Thomas | Pres, CEO, Dir | A - Grant | $0.00 | +23.0K | 23.0K | New | $0 | |
| 2023-05-02 | 2023-02-17 | GNLX | Thomas John | Dir | A - Grant | $0.00 | +9,000 | 479.0K | +2% | $0 | |
| 2023-05-02 | 2023-02-17 | GNLX | Mirabelli Mary | Dir | A - Grant | $0.00 | +1,000 | 1,000 | New | $0 | |
| I | 2023-01-31 | 2023-01-26 | GNLX | Zhang Qian | Associate VP, Research | P - Purchase | $6.25 | +200 | 200 | New | +$1,250 |
| DMI | 2023-01-30 | 2023-01-30 | GNLX | Woodward Gabe | Dir | C - Cnv Deriv | — | +8,176 | 5,378 | New | — |
| D | 2023-01-30 | 2023-01-30 | GNLX | Woodward Gabe | Dir | C - Cnv Deriv | — | +3,186 | 3,186 | New | — |
| DMI | 2023-01-30 | 2023-01-30 | GNLX | Szalay Aladar | 10% | C - Cnv Deriv | — | +1.00M | 2.26M | +79% | — |
| D | 2023-01-30 | 2023-01-30 | GNLX | Thomas John | Dir | C - Cnv Deriv | — | +470.0K | 470.0K | New | — |
Purchase Sale Sale after option exercise All abbreviations